Effects of concomitant use of hydrogen water and photobiomodulation on Parkinson disease: A pilot study.
Chien-Tai Hong, Chaur-Jong Hu, Hung-Yu Lin, Dean Wu · Medicine · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 18 patients with PD (age 30-80 years), this novel, proof-of-concept study demonstrated that PBM+H₂ therapy is safe and reduces disease severity. This small, pilot study suggests therapeutic potential, while larger randomized, placebo-controlled studies are needed to confirm the finding.
What the Researchers Studied
The study examined therefore, this study aimed to determine the safety and effectiveness of PBM + H₂ in patients with PD.
How Molecular Hydrogen Was Used
All the participants received daily PBM + H₂ therapy for 2 weeks.
What the Researchers Found
After 1 week of therapy cessation, UPDRS scores slightly increased but the improvement remained significant compared with the baseline.
H₂ Mechanisms / Biological Findings
The source material reviewed did not establish a specific molecular hydrogen mechanism for the reported findings.
Authors’ Conclusion
The authors concluded that this novel, proof-of-concept study demonstrated that PBM+H₂ therapy is safe and reduces disease severity. A larger-scaled clinical trial is warranted to completely investigate the effects of PBM + H₂ therapy on PD.